Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3 by Weilbaecher, Katherine N. et al.
 
775
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/03/775/11 $2.00
Volume 187, Number 5, March 2, 1998 775–785
http://www.jem.org
 
Age-resolving Osteopetrosis: A Rat Model Implicating
Microphthalmia and the Related Transcription Factor TFE3
 
By Katherine N. Weilbaecher,
 
*
 
 Christine L. Hershey,
 
*
 
Clifford M. Takemoto,
 
*
 
 Martin A. Horstmann,
 
*
 
 Timothy J. Hemesath,
 
*
 
 
 
Armen H. Tashjian, Jr.,
 
‡
 
 and David E. Fisher
 
*
 
From the 
 
*
 
Dana Farber Cancer Institute, Department of Pediatric Oncology, Harvard Medical School, 
 
Boston, Massachusetts 02115; and the 
 
‡
 
Department of Biological Chemistry and Molecular 
Pharmacology, Harvard Medical School and Department of Cancer Cell Biology, Harvard School of 
Public Health, Boston, Massachusetts 02115
 
Summary
 
Microphthalmia (Mi) is a basic helix-loop-helix–leucine zipper (b-HLH-ZIP) transcription
factor implicated in pigmentation, mast cells, and bone development. Two dominant-negative
 
mi
 
 alleles (
 
mi
 
/
 
mi
 
 and 
 
Mi
 
or
 
/
 
Mi
 
or
 
) in mice cause osteopetrosis. In contrast, osteopetrosis has not
been observed in a number of recessive 
 
mi
 
 alleles, suggesting the existence of Mi protein part-
ners important in osteoclast function. An osteopetrotic rat of unknown genetic defect (
 
mib
 
) has
been described whose skeletal sclerosis improves dramatically with age and that is associated
with pigmentation defects reminiscent of mouse 
 
mi
 
 alleles. Here we report that this rat strain
harbors a large genomic deletion encompassing the 3
 
9
 
 half of 
 
mi
 
 including most of the b-HLH-
ZIP region. Osteoclasts from these animals lack Mi protein in contrast to wild-type rat, mouse,
and human osteoclasts. Mi is not detectable in primary osteoblasts. In addition TFE3, a b-HLH-
ZIP transcription factor related to Mi, was found to be expressed in osteoclasts, but not osteoblasts,
and to coimmunoprecipitate with Mi. These results demonstrate the existence of members of a
family of biochemically related transcription factors that may cooperate to play a central role in
osteoclast function and possibly in age-related osteoclast homeostasis.
 
T
 
he osteoclast is a multinucleated giant cell derived
from the monocyte/macrophage lineage which forms
a ruffled membrane border and secretes a variety of special-
ized factors, including proteases, phosphatases, and protons
which break down bone matrix, releasing mineral ions into
the extracellular fluid (1, 2). Osteopetrosis is an abnormality
of bone remodeling caused by decreased osteoclastic bone
resorption producing skeletal sclerosis and reduced or ab-
sent marrow cavities. Several mouse models of osteopetro-
sis have led to new insights on bone remodeling and osteo-
clast function in development (3–11). Most, but not all, of
these mouse mutants display cell autonomous defects in os-
teoclast development or function. The 
 
op
 
/
 
op
 
 (osteopetrotic)
mouse contains an inactivating mutation in the M-CSF
gene which results in a severe deficiency of macrophages
and osteoclasts (10). The 
 
fos
 
-null mouse develops osteo-
petrosis associated with a lack of osteoclasts and an increase
in macrophage numbers (4, 5, 12). The 
 
src
 
 null mouse has
multinucleated osteoclasts that do not form a ruffled border
and that resorb bone matrix poorly (6, 9, 13). The 
 
mi
 
/
 
mi
 
microphthalmia
 
 
 
mutant mouse was recognized in the
1940’s (14) as an allele that produces severe osteopetrosis
associated with ocular and pigmentation defects (7, 8, 15,
16). 
 
mi
 
/
 
mi
 
 mice contain osteoclasts that harbor a variety of
morphologic defects, including diminished formation of
mature multinucleate osteoclasts, lack of ruffled mem-
branes, and diminished bone resorption (17).
The gene encoding mouse microphthalmia was cloned
in 1993 and found to encode a Myc-related basic helix-
loop-helix–leucine zipper
 
1
 
 (b-HLH-ZIP) protein (18, 19).
Biochemical studies (20) demonstrated a DNA binding
specificity for consensus sequence CA(C/T)(G/A)TG (20)
and its capacity to heterodimerize in vitro with three struc-
turally related b-HLH-ZIP factors, TFEB (21), TFE3 (22,
23), and TFEC (24, 25), but not Myc/Max (26), USF, or
other b-HLH-ZIP proteins (20). These three dimerization
partners (TFEB, TFE3, and TFEC) are less well under-
stood in terms of expression patterns, particularly in osteo-
clasts, although targeted disruption of TFE3 in lympho-
cytes impairs B cell activation (27). 
 
mi
 
/
 
mi
 
 mutant mice
 
1
 
Abbreviations used in this paper:
 
 1,25-(OH)
 
2
 
D
 
3
 
, 1,25 dihydroxyvitamin
D3; b-HLH-ZIP, basic helix-loop-helix-leucine zipper; Mi, microph-
thalmia; RT, reverse transcriptase; TF, transcription factor; TRAP, tar-
trate-resistant acid phosphatase.
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display defective eye development (related to pigment cell
abnormalities), complete lack of skin melanocytes, deafness
(related to absence of pigment cells in the inner ear), severe
defects in mast cells, and osteopetrosis. Mutations in human
microphthalmia have been detected in the autosomal dom-
inant hereditary deafness and pigmentation condition Waar-
denburg Syndrome type 2A (28, 29).
Biochemical analysis of a series of mouse microphthalmia
mutant alleles identified several dominant-negative muta-
tions that produced corresponding dominant pigmentation
defects in heterozygous mice (20, 30). Only two microphthal-
mia alleles (
 
mi
 
/
 
mi
 
 and 
 
Mi
 
or
 
/
 
Mi
 
or
 
) in the mouse (out of 
 
z
 
15
described) display osteopetrosis, whereas all display defects
in pigment cells (7, 16). Interestingly, the two osteopetrotic
alleles both contain dominant negative mutations in the ba-
sic domain that disrupt DNA contact without perturbing
dimerization (20, 31) and affect pigmentation even in het-
erozygotes. In b-HLH-ZIP proteins, the basic domain
contacts DNA through an induced alpha helix while the
HLH-ZIP mediates dimerization and positions the basic
domain to lie optimally within the major groove of DNA
(20, 26, 32-34). A variety of mutations for the pigmenta-
tion phenotype have been characterized. Mutations in the
basic region which disrupt DNA binding of the protein
confer pigmentation defects in a semidominant pattern of in-
heritance, whereas mutations in the helix-loop-helix or other
essential parts of the gene result in the absence of pigmen-
tation in a recessive pattern of inheritance. Osteopetrosis
has not previously been recognized for any of the recessive
microphthalmia (
 
mi
 
) mutant alleles. This implies that there
may be another Mi family member expressed in osteoclasts
that could substitute for Mi deficiency. However, basic re-
gion mutations in Mi could potentially disable the mutant
as well as normal partner protein(s).
In 1989, a spontaneous osteopetrotic mutation in the rat
was described in which homozygotes display osteopetrosis
at birth, but this defect in bone resorption dramatically im-
proves with age (35). Because of associated small eyes and
white coat color, the allele was called microphthalmia blanc
(
 
mib
 
), although the nature of the mutation is to date un-
known. The 
 
mib
 
 mutation is autosomal recessive, showing
expression in homozygotes (
 
mib
 
/
 
mib
 
) with absence of skin
and fur pigmentation, small eyes, and defects of incisor
tooth eruption (36). The 
 
mib
 
 locus has previously been
suggested to be different from microphthalmia (
 
mi
 
), inci-
sorless (
 
ia
 
), osteopetrotic (
 
op
 
), or hypodactyly (
 
hd
 
) loci based
on phenotypic differences and rough linkage estimates (35).
Cielinski and Marks (37, 38) have shown that the 
 
mib
 
/
 
mib
 
mutant osteoclasts in newborn animals are decreased in num-
ber, do not form a ruffled border, and show decreased lev-
els of mRNA for carbonic anhydrase II and tartrate-resistant
ATPase. However, by the fourth postnatal week, the 
 
mib
 
/
 
mib
 
mutant osteoclast number, resorptive function, and cell-
specific gene expression have returned to normal, and the
skeletal sclerosis is significantly reduced (37, 38).
In this paper, we demonstrate that Mi is abundantly ex-
pressed in wild-type mouse, rat, and human osteoclasts by
immunohistochemistry and Western and Northern blot
 
analyses. Immunohistochemical staining localizes Mi to os-
teoclast nuclei. Mouse calvarial osteoblasts in primary cul-
ture and the ST2 murine osteoblast cell line do not express
Mi. Given the phenotypic similarities of the 
 
mi
 
/
 
mi
 
 mutant
mouse and the 
 
mib
 
/
 
mib
 
 osteopetrotic rat, we have exam-
ined the microphthalmia locus in the 
 
mib
 
 rat and discov-
ered a large deletion in the 3
 
9
 
 half of the 
 
mi
 
 gene starting in
the basic region. The age-dependent remission of osteo-
petrosis in the 
 
mib
 
 mutant led us to search for Mi-related
transcription factors in osteoclasts. We show here that
TFE3 is abundantly expressed by osteoclasts and is found in
coimmunoprecipitates with Mi, suggesting that a discrete
transcription factor family may play a critical, age-depen-
dent role in osteoclasts.
 
Materials and Methods
 
Animals.
 
Animals used in this study were the offspring of 
 
1
 
/
 
mib
 
and 
 
mib
 
/
 
mib
 
 rats (originally derived from the stock of Dr. Rene
Moutier, CNRS, Orleans, France [35] and generously donated
by Dr. Sandy Marks, Jr., University of Massachusetts Medical
School, Worcester, MA). The animals were bred and maintained
at Harvard Medical School in accordance with Harvard guidelines.
All animals were given powdered and solid rat food. Homozy-
gous mutant animals (
 
mib
 
/
 
mib
 
) were easily identified by their
white coat color and small eyes. 
 
1
 
/
 
mib
 
 and 
 
1
 
/
 
1
 
 (wild-type) rats
are indistinguishable phenotypically. 
 
1
 
/
 
1
 
 rats are defined as ani-
mals that have delivered at least 20 phenotypically normal offspring
when mated with 
 
mib
 
/
 
mib
 
 rats. Primary mouse osteoclast cultures
were made using spleen and bone marrow from 6–12-wk-old
C57 black mice.
 
Osteoclast Cultures. mib
 
/
 
mib
 
 and wild-type rat bone marrow
from 6-mo-old rats was harvested by flushing cold PBS through
the femurs and tibiae with a 22-gauge needle. Rat osteoclast cul-
tures (39) were made using 1.5 
 
3
 
 10
 
6
 
 bone marrow cells/ml in
MEM containing 10% fetal bovine serum and 10
 
2
 
8
 
 M 1,25 dihy-
droxyvitamin D3 (1,25-(OH)
 
2
 
 D
 
3
 
; gift of Dr. Uskokovich, Hoff-
man-LaRoche, Nutley, NJ). Cultures were fed every 3 d by re-
placing one half of the spent medium with fresh medium. Mouse
osteoclast cultures (40, 41) were made using primary mouse cal-
varial osteoblasts (4 
 
3
 
 10
 
4
 
 cells/ml) obtained as previously de-
scribed (42) and cocultured with spleen from 6–12-wk-old mice
(6 
 
3
 
 10
 
5
 
 cells/ml) in the above medium. Cultures were fed every
3 d by replacing one half of the old medium with fresh medium.
Human osteoclasts cultures were made using 10
 
6
 
 cells/ml of Ficoll-
fractionated whole normal donor adult (ages 18–60 yr) bone mar-
row or 2 
 
3
 
 10
 
6
 
 cells/ml of Ficoll-fractionated CD34-depleted
normal human bone marrow. Bone marrow was cultured in MEM
media with 20% horse serum (Hyclone Laboratories, Logan, Utah)
and 10
 
2
 
8
 
 M 1,25-(OH)
 
2
 
 D
 
3
 
) (43–45). Cultures were refed every
week by changing one half of the media. After 14 d, cultures were
refed with the above media supplemented with 10 ng/ml human
recombinant M-CSF (R & D Systems, Inc., Minneapolis, MN).
 
Immunohistochemistry and Tartrate Resistant Acid Phosphatase Stain-
ing.
 
Mi antibodies (46) were generated against the NH
 
2
 
 termi-
nus Taq-Sac fragment of human Mi expressed as a His-fusion and
shown not to cross react with other b-HLH-ZIP factors by DNA
mobility shift assay (data not shown). Cells were grown on glass
chamber slides (Fisher Scientific, Pittsburgh, PA) and were fixed
with 3% formaldehyde in PBS for 30 min and washed, followed
by 10 min in 1% Triton X-100. After another PBS wash, slides
were incubated with 3% H
 
2
 
O
 
2
 
 to remove endogenous peroxi- 
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dase. The anti-Mi monoclonal antibody 1:10–1:40 or anti-TFE3
monoclonal antibody (PharMingen, San Diego, CA) 1:250–1:500
was added for 1 h. The Vecta-stain Elite kit (Vector Laboratories,
Burlingame, CA) was then used for immunohistochemical stain-
ing according to the manufacturer’s instructions. The diami-
nobenzidine reagent (Vector Laboratories) was applied for 2–4
min and the slides were analyzed under light microscopy. Tartrate
resistant acid phosphatase (TRAP) staining was performed ac-
cording to the manufacturer’s instructions using the Sigma TRAP
kit (Sigma Chemical Co., St. Louis, MO). TRAP is an osteoclast
marker.
 
Immunoprecipitation and Western Blotting.
 
Immunoblots of cell
cultures containing osteoclast-like cells were generally preceded
by immunoprecipitation that concentrated the antigen and per-
mitted efficient on-plate cell lysis in 1% Triton X-100 detergent
with 150 mM NaCl, Tris, pH 7.6, 2 
 
m
 
g/ml aprotinin, 2 
 
m
 
g/ml
leupeptin, 200 mg/ml trypsin inhibitor, 500 mg/ml antipain, 10 mM
sodium fluoride, 1 mM sodium vanadate, 2 mM PMSF, 20 mM
sodium pyrophosphate and 10 mg/ml pepstatin. The soluble frac-
tion was incubated for 1–2 h on ice with appropriate antibodies
and washed protein A agarose beads (GIBCO BRL, Gaithers-
burg, MD) were added. The mixture was rotated at 48C for a
minimum of 12 h. Beads were then washed three times with
PBS, resuspended in 2% SDS/1% glycerol and boiled for 5 min,
and eluted proteins were resolved on an 8% SDS–polyacrylamide
gel (4% SDS–polyacrylamide stacking gel) run at 200 V for 6–8 h.
Proteins were transferred to nitrocellulose with methanol–glycine
electrotransfer (Bio-Rad Labs., Hercules, CA). The membrane
was blocked in 5% milk for 1 h at room temperature or overnight
at 48C. After washing in TBST (10 mM Tris, pH 7.6, 150 mM
NaCl, and 0.5% Tween 20), 1:40 dilution of the Mi antibody or 1:
500 dilution of TFE3 antibody or a tubulin 1:500 dilution (Sigma
Chemical Co.) was added for 1 h at room temperature. After
washing, goat anti–mouse horseradish peroxidase–conjugated an-
tibody (Cappel, West Chester, PA) was added for 40 min. After
washing, the enhanced chemiluminescence reaction was per-
formed (Amersham Corp., Arlington Heights, IL).
PCR and Southern Analysis of Genomic DNA. Genomic DNA
was extracted from the tails of mib/mib, 1/mib, and 1/1 animals
using the Puregene kit (Gentra Systems, Plymouth, MN) accord-
ing to manufacturer’s instructions. The genomic PCR reactions
used 50 ng of purified genomic DNA under the following condi-
tions: 948C for 2 min, 578C for 1 min, and 728C for 2 min except
for exon 9, where an annealing temperature of 608C for 1 min
was used for 30 cycles. For Southern analysis, 10 mg of genomic
DNA was digested with each of the following restriction enzymes:
Hinc II, Xba I, and Bam HI, using the manufacturer’s instruc-
tions (New England Biolabs, Beverly, MA). The digested DNA
was electrophoresed on a 1% agarose/Tris borate EDTA (TBE)
gel. The gel was denatured with 0.25 M HCl followed by 0.5 M
NaOH/1.5 M NaCl, and equilibrated with Tris, pH 8.0/1.5 M
NaCl. The DNA was transferred to nylon membranes, UV cross-
linked, and prehybridized for 30 min with Quik-Hyb (Strat-
agene, La Jolla, CA) at 658C. 32P-dCTP radiolabeled full-length
Mi cDNA was made using the Stratagene Prime-it random label-
ing kit. 106 cpm/ml of Quik-Hyb solution was used and hybrid-
ization was performed at 658C for 2 h.
Reverse Transcriptase PCR and Northern Analysis. Total cellular
RNA from heart tissue and cultured cells was isolated using RNAzol
(Tel-Test, Friendswood, TX) according to the manufacturer’s in-
structions. A series of primers to mouse microphthalmia exons 5–9
were synthesized: 59 exon 5 CCCGTCTCTGGAAACT-
TGATCG; 59 exon 6 CGTGTATTTTCCCCACAGAGTC; 59
exon 8 GACATGCGGTGGAACAAGGG; 59 exon 9 GAGCTG-
GAGATGCAGGCTAG; 39 exon 5 GTTGGGAAGGTTGGC-
TGGAC; 39 exon 6 CTGCCTCTCTTTAGCCAATGC; 39
exon 7 GGATCATTTGACTTGGGGATCAG; 39 exon 8 CTG-
TACTCTGAGCAGCAGGTG; 39 exon 9 GCTCTCCGGCA-
TGGTGCCGAGG. cDNA was made using a reverse transcriptase
(RT) (PCR kit) (GIBLO BRL, Gaithersburg, MD). 1–5 mg of
total RNA was used for each CDNA reaction along with 30–100
pmol of 39 primer and 200 U of SuperScript II TM reverse tran-
scriptase and incubated for 50 min at 428C. 2–4 ml of the 20 ml
cDNA reaction mixture was used for PCR reactions including
Taq polymerase (Fisher Scientific Co., Pittsburgh, PA), dNTP’s
(Pharmacia Biotech, Piscataway, NJ), and PCR buffer (Perkin-
Elmer Corp., Norwalk, CT) and with incubations at 948C for 2 min,
578C for 1 min, and 728C for 2 min for 30 cycles (annealing tem-
perature for reactions containing 59 exon 6 was 678C; for 59 exon 7
was 578C; and for 59 exon 8 and 59 exon 9 was 628C). 25–50 ml of
the 100 ml reaction mixtures were resolved by electrophoresis in
nondenaturing 8–10% polyacrylamide gels. Negative controls
were performed with water in place of DNA. The RT-PCR
product from 59 exon 5 and 39 exon 8 for wild-type rat was gel
purified and sequenced. The sequence was confirmed from four
independent PCR reactions.
Mi expression was examined using Northern analysis with 20 mg
of total RNA loaded on a formaldehyde gel, transferred to nylon
membranes, and probed with radiolabeled full length mi DNA for
2 h at 658C in Quik-hyb solution. For loading control, a radiola-
beled 500-bp Xba I/Hind III fragment of the human glyceralde-
hyde 39 phosphate dehydrogenase was used.
Cell Lines. NIH3T3 (mouse fibroblasts), L cells (murine con-
nective tissue line), BHK (hamster kidney cell line), and B16
(murine melanoma) were grown in DMEM with 10% fetal bo-
vine serum. ST2 (Riken Cell Bank, Tsukuba Science City, Japan)
was grown in RPMI 1640 and 10% FBS. The mast cell line C57
(gift of Dr. Stephen Galli, Harvard Medical School, Cambridge,
MA) was grown in DMEM with 10% fetal bovine serum and 2 3
1025 M 2-b mercaptoethanol. The human melanoma cell line,
501MEL (gift of Dr. Ruth Haliban, Yale Medical School, New
Haven, CT) was grown in F10 media with 10% fetal bovine serum.
Results
Expression of Mi in Cultured Osteoclasts. Osteoclasts were
prepared by two standard techniques. Mouse calvarial os-
teoblasts and spleen cells were cocultured in the presence of
1,25-(OH)2D3 to generate osteoclast-like cells. This tech-
nique produces osteoclasts that express calcitonin receptors
and TRAP, and make resorption pits in bone (2, 42). Hu-
man osteoclast-like cells (HOCs) were grown in the pres-
ence of 1,25-(OH)2D3 and M-CSF. HOCs cultured in this
manner have also been shown to express calcitonin recep-
tors and TRAP, and make resorption pits in bone (43, 44).
Immunohistochemical staining was performed on day 12
for mouse osteoclast-like cells and day 21 for HOCs using
two separate monoclonal antibodies prepared against a
novel peptide from Mi (see Materials and Methods). Fig. 1
shows nuclear staining by the anti-Mi antibody in the
multinucleated osteoclast-like cells. The surrounding cal-
varial osteoblasts showed no Mi staining. The human mela-
noma cell line (501 MEL) served as a positive control (46).778 Age-resolving Osteopetrosis: Model Implicating Microphthalmia and TFE3
L-cells, NIH3T3, and BHK showed no Mi staining (data
not shown).
Protein extracts were made from various cell types in-
cluding ST2, L cells, NIH3T3, as well as HOCs. There are
two known forms of Mi differing by 66 amino acids at the
NH2 terminus that likely initiate from different promoters
and are spliced to the same downstream exon (31). The
shorter forms are expressed in melanocytes (31) and run as
two bands at 54 and 60 kD. These melanocyte isoforms
have been shown by two-dimensional tryptic mapping to
differ in c-Kit–induced phosphorylation (46). The longer
nonmelanocyte Mi form runs as a cluster of species at z70
kD in osteoclasts (Fig. 2 A) and in B16 melanoma cells (but
not other melanoma cell lines [46] as well as mast cells and
heart (data not shown). The presence of multiple closely
migrating bands suggests that Mi may undergo modifica-
tions in osteoclasts, a possibility which would be consistent
with its kit-induced phosphorylation in melanoma cells
(46). 3T3, ST2, and L cells do not show any Mi-specific
bands (Fig. 2 A). It should be noted that although immu-
nohistochemistry appears to identify Mi (and TFE3, see
below) only in osteoclast-like cells, these cultures do repre-
sent mixed populations and we cannot exclude the pos-
sibility of a contribution in gel signal from nonosteoclasts.
All of these studies were carried out in mixed primary bone
marrow and spleen cultures because of the lack of availabil-
ity of purified osteoclast-derived cell lines (2). Previously,
Mi expression has been demonstrated at the RNA level in
Figure 1. Immunohistochemical staining for Mi in osteoclasts. A, B, D, and E show nuclear localization of Mi; there is no counterstaining. (A) 501
Mel human melanoma cell line. (B) Multinucleate human osteoclast-like cells after 21 d in culture. (D) Murine osteoclast-like cocultures after 12 d in cul-
ture; arrowhead points to nonstaining calvarial-derived osteoblast-like cells and arrow points to multinucleated osteoclast. (E) Murine osteoclast-like co-
cultures (as in D) with second step antibody alone showing little background staining. (C) Human osteoclast cultures (day 21) stained with Wright-
Giemsa. (F) Human osteoclast cultures (day 21) stained with TRAP stain.779 Weilbaecher et al.
melanocytes, heart, and mast cells (18, 31). Northern anal-
ysis from cultured primary osteoclast-like cells reveals Mi
mRNA at 5.6 Kb (Fig. 2 B). Mast cells exhibit the same
size species (Fig. 2 B), in agreement with previous studies
(18, 31). 
Figure 3. Exon mapping of Mi in the mib/mib rat. (A) Schematic of the microphthalmia coding region. Act, transactivation domain; b, basic region;
HLH, helix-loop-helix; ZIP, leucine zipper. 59 and 39 primers were constructed at the boundaries of exons 5–9. (B) Genomic PCR: PCR reactions us-
ing primers from the 59 and 39 ends of exons 5, 6, 8, and 9 on genomic DNA from mib/mib (Mib) and wild-type (WT) rats are shown. Control (-) lacked
template DNA. Exon 5 PCR product is 96 bp, exon 6 is 74 bp, exon 8 is 222 bp and exon 9 is 147 bp. Exon 7 is too small and AT rich to map by this
method. (C) RT-PCR: a series of 39 primers downstream from exon 5 were used to map the deletion in the mib/mib rat. In all cases the 59 primer is at
the 59 end of exon 5. Exons 5 and 6 (59 exon 5 to 39 exon 6) encodes a 168-bp doublet seen in both mib/mib RNA (Mib) and wild-type (WT) RNA. Ex-
ons 5–7 (59 exon 5 to 39 exon 9) is 266 bp in length. Exons 5–8 (59 exon 5 to 39 exon 8) is 414 bp and exons 5–9 (59 exon 5 to 39 exon 9) is 636 bp. The
doublet arises from the previously described 18-bp alternative splice at the exon 5 and 6 boundary (31) and was confirmed by sequencing (data not
shown). Absence of amplifiable sequences in exons 8 and 9 by genomic PCR and in 7–9 by RT-PCR suggest the presence of a large deletion within Mi.
Figure 2. Mi immunoprecipitation and Northern blotting. (A) Immu-
noprecipitation and Western blotting shows that the human long-term
marrow osteoclast cultures have an z70 kD form of Mi (nonmelanocyte
form). B16 murine melanoma has this z70 kD species in addition to the
more predominant melanocyte specific forms at 54 kD and 60 kD.
NIH3T3, L-cells, and ST2-like cells do not express detectable Mi. (B)
Northern blot analysis shows that the Mi mRNA transcripts in osteoclast
cultures comigrates with Mi mRNA from mast cells with a size of z5.6
kb. Glyceraldehyde 39 phosphate dehydrogenase probe confirms levels of
RNA loaded in each lane.780 Age-resolving Osteopetrosis: Model Implicating Microphthalmia and TFE3
Mapping the Mutation in the mib Rat. To examine the mi-
crophthalmia gene in the mib/mib rat, a series of PCR prim-
ers was used to amplify both genomic DNA and RNA
from mib/mib and genetically matched wild-type rats. Exon
mapping of genomic DNA was performed using 59 and 39
primers at the ends of each exon from exon 5 through 9
except for exon 7, which is short and very AT-rich, thus
rendering PCR mapping of this exon technically difficult.
Bands of the expected sizes were identified for exons 5 and
6 in both the mib/mib and wild-type DNA samples (Fig. 3 B).
However, exons 8 and 9 were only identified in wild-type
samples, and not in mib/mib.
RT-PCR was performed on heart RNA from wild-type
and mib/mib rats using a 59 primer in exon 5 and a series of
39 primers spanning exon 6 through exon 9 (Fig. 3 C). A
doublet is seen throughout this series of RT-PCR products
due to an 18-bp alternative splice at the beginning of exon
6 (31), which was confirmed by sequencing (data not shown).
Using 59 exon 5 and 39 exon 6 primers, Mi-specific bands of
the expected size were identified in both the mib/mib and
wild-type RNA samples. 59 exon 5 and 39 exon 7 primers
gave the appropriate products only in the wild-type RNA
sample with no corresponding band in the mib/mib samples.
Similarly for 39 exons 8 and 9, only the wild-type sample
showed bands of the expected sizes. Data from genomic
exon mapping and RT-PCR thus indicate that there is a
deletion in Mi of all or part of exon 7, and in exons 8 and 9
in the mib/mib rat.
Mi Southern blot analysis of mib/mib, 1/mib, and 1/1
genomic DNA was performed using BamHI, HincII, and
XbaI (Fig. 4 A). At least one distinct band was absent in the
mib/mib lanes for each of these enzymes, consistent with
the PCR data indicating genomic deletion of a region
within  mi. For example, with XbaI, the 2.7-kb band is ab-
sent in the mib/mib lane. The lack of apparent new bands in
mib is consistent with lack of a reciprocal translocation (also
suggested by absence of signal in 39 exons by genomic exon
mapping). These data indicate that the microphthalmia
gene has undergone a large genomic deletion in the mib/
mib osteopetrotic rat.
The sequence of rat microphthalmia for exons 5–9 was
determined from multiple independent PCR products and
is shown in Fig. 5. Mi is highly conserved between human
and mouse as well as in the rat in the b-HLH-ZIP region.
Fig. 5 shows the sequence of the rat as compared to mouse
and human mi. Over the 331 bp examined, there are 20
single base differences between mouse and rat, none of
which alter the coding sequence. Of the 20 positions
where mouse and rat differ, the human sequence matched
mouse in 8, matched rat in 8, and was different from both
in 4.
Evaluation of mib/mib Mutant Osteoclasts. mib/mib and wild-
type rat bone marrow from 6-mo-old rats were harvested
and cultured in the presence of 1,25-(OH)2 D3 to produce
osteoclast-like cells. TRAP stains were performed at day 13
and revealed equivalent numbers of multinucleated TRAP
positive cells per high powered field in both cultures (data
not shown) consistent with previous reports that mib/mib
osteoclast number and function return to normal after 4 wk
of age (38). However, immunoblots for Mi revealed no de-
tectable Mi protein in the mutant osteoclasts compared to
Figure 4. Partial deletion of
mi in the mib/mib rat and mutant
osteoclasts. (A) Southern Blot:
genomic DNA from mib/mib,
1/mib, and 1/1 rats were di-
gested with XbaI, BamH1, and
HincII, and probed with radio-
labeled full-length mi mouse
cDNA. The pattern is notewor-
thy for absent bands in the mib/
mib samples compared with het-
erozygote or wild-type samples.
(B) Protein extracts were made
from day 13 cultured mib/mib os-
teoclasts and wild-type rat osteo-
clasts (WT) and immunoprecipi-
tated with Mi antibody. Western blotting with the Mi antibody after
SDS-PAGE is shown. Immunoglobulin heavy chain (IgH) runs at 50 kD
and Mi osteoclast form runs at z70 kD. Western blotting with anti–rat a
tubulin antibody demonstrates protein loading. No Mi is detected in mib/
mib osteoclasts.
Figure 5. Rat mi sequence for exons 6–9. The sequence is highly con-
served between rat, human, and mouse with only minor nucleotide
changes. The only mutations that alter the amino acid sequence are de-
picted by (#) aspartic acid (mouse and rat) to glutamic acid (human) and
(*) valine (mouse and rat) to isoleucine (human).781 Weilbaecher et al.
wild-type (Fig. 4 B). Although the antibody epitope is not
deleted, no truncated forms of Mi were detected, suggest-
ing instability of the truncated RNA or protein (or both).
Expression of TFE3 in Cultured Osteoclasts. Improvement
of the osteoclast defect in the mib/mib rat and the recessive
inheritance pattern of osteopetrosis in dominant negative
mouse mutants (20) suggest that an unidentified partner
protein may exist for Mi in osteoclasts. We have previously
demonstrated the ability of several related b-HLH-ZIP fac-
tors to heterodimerize in vitro with Mi (20). Immunohis-
tochemistry and immunoblot analyses were carried out to
examine mouse osteoclasts for the presence of TFE3. Im-
munostaining demonstrated strong staining for TFE3 in the
nuclei of osteoclasts (Fig. 6 A). In contrast, osteoblasts do
not express detectable TFE3. Mi runs at z70 kD in osteo-
clasts and TFE3 migrates at 59 kD in osteoclasts. L-cells
(from which murine TFE3 was cloned) express TFE3 but
not detectable Mi. In addition, anti-TFE3 blotting of Mi
immunoprecipitates from osteoclasts revealed significant
TFE3 protein (Fig. 6 B). Approximately 10% of the input
TFE3 was detected in Mi immunoprecipitates indicating
significant Mi TFE3 heterodimerization (Fig. 6 B). As a
specificity control, no TFE3 was seen in anti-Mi immuno-
precipitates of L cells (Fig. 6 B) or in isotype-matched (to
anti-Mi) control immunoprecipitates of osteoclasts (data
not shown). Other experiments have demonstrated the re-
ciprocal coimmunoprecipitation of Mi by anti-TFE3 (data
not shown). These findings suggest that both TFE3 and Mi
proteins are present in osteoclast-like cells and may het-
erodimerize in vivo, although this analysis cannot discrimi-
nate heterodimers that form after extract preparation.
Immunohistochemical staining for TFE3 in wild-type
and mib/mib cultured rat osteoclasts is shown in Fig. 7.
TFE3 is present in both wild-type and mib/mib osteoclast-
like cells in a nuclear pattern. Mi staining was also per-
formed and is seen in wild-type rat osteoclast-like cells but
not in mib/mib. Second step antibody staining alone shows
little background staining (data not shown). The asterisk
denotes the nonstaining stromal cells in these bone marrow
cultures. TFE3 is thus detectable in both mouse and rat os-
teoclast-like cells including mib/mib, consistent with a po-
tential ability to interact with or partially compensate for
Mi deficiency.
Discussion
Mice with certain mutations in mi develop osteopetrosis
that, based on Mi’s abundant expression in osteoclasts but
not stromal cells, likely reflects a cell autonomous defect.
This is also consistent with hematopoietic transplantation
studies that corrected the mi/mi osteopetrotic phenotype
(8). The mib rat develops osteopetrosis with dramatic age-
dependent changes. mib/mib osteoclasts resorb bone poorly
and do not have a ruffled border at birth. However, after
birth, osteoclasts begin to regain normal morphology and
osteoclastic activity, and the osteopetrosis largely resolves,
with the exception of a persistent long-term failure of inci-
sor eruption (36). In this report we demonstrate that mib/
mib rats harbor a large deletion in the 39 half of the mi gene
that eliminates most of the b-HLH-ZIP region. The dele-
tion probably starts within the intron separating exons 6
and 7 and truncates the gene in the region coding for the
basic domain. The age-resolving osteopetrotic phenotype
prompted us to search for a transcription factor partner for
Mi that might in principal rescue mib/mib osteoclasts.
TFE3, a b-HLH-ZIP transcription factor (21, 22), was
found within the nuclei of mouse and rat osteoclasts (in-
cluding mib/mib), but not osteoblasts. Moreover TFE3 was
also found to coimmunoprecipitate with Mi from wild-
type cells. These data indicate that a distinct family of re-
lated b-HLH-ZIP transcription factors is expressed in os-
teoclasts and suggests that these factors may collectively
play a role in the function of osteoclasts in bone resorption.
Interestingly, the majority of mouse strains harboring mi
mutations have not been recognized to develop osteo-
petrosis. Only mi/mi and Mior/Mior strains display osteo-
petrosis, and these two notably contain basic region defects
(31) that function as dominant negative proteins in vitro
(20). The only other known basic domain mutant of mi
(Miwh/Miwh) differs in that the presence of an alternatively
spliced 6-amino acid insert NH2-terminal to the basic do-
main rescues its heterodimeric DNA binding capacity to
wild-type levels (20), which may explain why Miwh/Miwh
animals do not develop osteopetrosis. These observations
suggest the functional relevance of Mi heterodimers in-
volving other family member(s) in vivo. It was anticipated
that the mutation in mib rats might also be dominant nega-
tive, by crippling DNA binding independently of dimeriza-
tion. However, the large genomic deletion removes most
of the basic domain and all of the dimerization region
(HLH-ZIP) precluding the formation of species analogous
to the mouse osteopetrotic (basic region mutations) mi/mi
and Mior/Mior alleles. Athough the resulting protein should
be profoundly truncated and could in principal be domi-
nant negative through expression of a remaining domain,
such a species is not readily detected within mib osteoclasts
by Western blotting or immunohistochemistry, and it is
likely that the protein or its mRNA undergo accelerated
degradation. An alternative hypothesis is that TFE3 or
other heterodimeric protein partners are expressed later in
osteoclast development than Mi, resulting in delayed osteo-
clast maturation and function. Mi could also regulate the
transcription of TFE3 and other family members and this
could explain the delay in osteoclast restoration of func-
tion. The dominant-negative mouse alleles display domi-
nant phenotypes with respect to pigmentation (white belly
spots in heterozygotes). Unfortunately ventral midline pig-
mentation cannot be assessed in mib heterozygotes because
the background rat strain is black hooded (i.e., wild-type
animals have a completely white belly).
There are several potential explanations for the presence
of osteopetrosis with a mi allele (mib) that is unlikely to act
as a dominant negative mutation. The osteopetrosis in mib
is less severe than that seen in the mouse mi alleles. It may
thus represent a more subtle osteoclast defect that was here-
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The improvement with age may, in particular, prevent rec-
ognition of the phenotype in older animals. The osteoclast
defect may occur during gestation and already begin im-
proving by the neonatal period. In fact, careful character-
ization of the osteopetrosis in Mior/Mior has also revealed
evidence of phenotypic changes with age (16). Interest-
ingly, in this case the osteopetrotic indices first worsen and
then improve somewhat over 3–8 mo. The age-dependent
remission may be the result of either diminished require-
ment for Mi protein or enhanced rescue by another fac-
tor(s). Additional studies that compare temporal expression
of Mi, TFE3, and other b-HLH-ZIP factors may shed
more light on the age-specific osteoclast phenotype.
A direct comparison of the mib mutation with the other
osteopetrotic mutations in Mi thus reveals a correlation in
the relative mildness of mib skeletal defects with the inabil-
ity of this deletion to dominantly affect partner proteins. It
is not currently known whether expression of Mimi or Mior
is maintained within the mutant osteoclasts, but it is rea-
sonable to expect that these small single residue mutations
are likely to produce stable gene products, as has been
demonstrated in heart tissue of the mutant mice (31). In
contrast, the large deletion in mib results in no detectable
gene product (mRNA or protein), presumably due to pre-
mature degradation or precursor gene products. Although
it is important to consider the contribution of deleted do-
mains COOH-terminal to the HLH-ZIP region in mib,
these are as yet poorly characterized although the proline-
rich COOH-terminal region is a plausible transactivation
motif.
Future studies will be needed to determine whether ex-
pression levels of TFE3 (as well as Mi and other b-HLH-
ZIP factors) change during skeletal development and aging.
Although it is plausible that the age-effect and lack of se-
vere osteopetrosis in mouse recessive mi alleles is due to
compensation by other b-HLH-ZIP factors, this possibility
is by no means proven by the current studies. Genetic ma-
nipulations, such as analysis of knockout mice, may be
more decisive. It also remains to be seen whether these
age-dependent changes reflect simple compensation in a
pathologic setting or a change in transcription factor usage
that occurs during normal maturation/aging. Since osteo-
clast function clearly changes with age and other extracel-
lular signals, the identification of factors that reflect these
changes may provide mechanistic clues to the problems of
osteopetrosis and osteoporosis.
Our findings place microphthalmia among a handful of
genes that may be important to osteoclast function. Mi may
be of particular interest because of recent evidence that it is
a signal responsive factor that is phosphorylated and be-
comes more transcriptionally active upon c-Kit stimulation
in melanocytes (46). Similar signaling pathways may exist
in osteoclasts and could regulate both Mi and its partners.
The presence of multiple migrating species of Mi and
TFE3 in osteoclasts is consistent with this possibility, which
is currently being examined. It will be of interest to deter-
mine whether Src, M-CSF, and/or Fos modulate the activ-
ity of Mi because mice defective in these factors also harbor
osteoclast defects of varying magnitudes. Tyrosinase and re-
lated pigment enzyme genes are important targets of Mi in
melanocytes (47–49). Mouse mast cell protease 6 (MMCP-
6) and c-Kit are likely to be important targets of Mi in mast
cells (46, 50–52). Mi and/or other b-HLH-ZIP family
members probably regulate genes related to osteoclast re-
sorptive function because of the poor bone resorption of
mutant mi/mi osteoclasts. Transcriptional targets for Mi and
TFE3 in osteoclasts have yet to be identified, but their elu-
cidation may shed important light on osteoclast biology.
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Figure 6. TFE3 expression and coimmunoprecipitation with Mi in osteoclasts. (A) TFE3 immunohistochemical staining of murine cocultured osteo-
clast-like cells. Arrow points to staining of multinucleated osteoclast-like cells with TFE3 antibody. Arrowhead points to nonstaining murine calvaria–
derived osteoblast-like cells. (B) Extracts from murine osteoclast-like cells or L cells were subjected to immunoprecipitation (IP) with monoclonal anti-
bodies against Mi or TFE3, resolved by SDS-PAGE, and immunoblotted with antibodies to Mi or TFE3 as indicated. Anti-Mi coimmunoprecipitates
TFE3 from osteoclasts (but not from L cells, which lack Mi, but contain TFE3). IP using a monoclonal antibody isotype matched to anti-Mi fails to pre-
cipitate TFE3 from osteoclasts as well (data not shown).
Figure 7. Immunohistochemical staining for Mi and TFE3 in wild-type and mib/mib cultured rat osteoclasts from day 12 bone marrow cultures. Mi lo-
calizes to the nucleus in wild-type multinucleated osteoclast-like cells, but there is no Mi nuclear staining in the mib/mib osteoclast-like cells. TFE3 nu-
clear staining can be seen in both wild-type and mib/mib osteoclast-like cells. Nonstaining stromal cells can be seen in the wild-type representative fields
for Mi and TFE3 (denoted by *).784 Age-resolving Osteopetrosis: Model Implicating Microphthalmia and TFE3
References
1. Chambers, T.J. 1985. The pathobiology of the osteoclast. J.
Clin. Pathol. 38:241–252.
2. Suda, T., N. Takahashi, and T. Martin, Jr. 1992. Modulation
of osteoclast differentiation. Endocr. Rev. 13:66–80.
3. Popoff, S., and S. Marks. 1995. The heterogeneity of the os-
teopetroses reflects the diversity of cellular influences during
skeletal development. Bone. 17:437–445.
4. Grigoriadis, A.E., Z. Wang, M. Cecchini, W. Hofstetter, R.
Felix, H. Fleisch, and E. Wagner. 1994. c-Fos: a key regula-
tor of osteoclast-macrophage lineage determination and bone
remodeling. Science. 266:443–448.
5. Grigoriadis, A.E., Z.Q. Wang, and E.F. Wagner. 1995. Fos
and bone cell development: lessons from a nuclear oncogene.
Trends Genet. 11:436–441.
6. Soriano, P., C. Montgomery, R. Geske, and A. Bradley.
1991. Targeted disruption of the s-src proto-oncogene leads
to osteopetrosis in mice. Cell. 64:693–702.
7. Murphy, H. 1973. The osteopetrotic syndrome in the mi-
crophthalmic mutant mouse. Calcif. Tissue Res. 13:19–26.
8. Walker, D. 1975. Bone resorption restored in osteopetrotic
mice by transplants of normal bone marrow and spleen cells.
Science. 190:784–785.
9. Boyce, B., T. Yoneda, C. Lowe, P. Soriano, and G. Mundy.
1992. Requirement of pp60c-src expression for osteoclasts to
form ruffled borders and resorb bone in mice. J. Clin. Invest.
90:1622–1627.
10. Yoshida, H., S. Hayashi, T. Kunisada, M. Ogawa, S. Nishikawa,
H. Okamura, T. Sudo, L.D. Shultz, and S. Nishikawa. 1990.
The murine mutation osteopetrosis is in the coding region of
the macrophage colony stimulating factor gene. Nature. 345:
442–444.
11. Wisner-Lynch, L., V. Shalhoub, and S.C. Marks, Jr. 1995.
Administration of colony stimulating factor–1 to toothless os-
teopetrotic rats normalizes osteoblast, but not osteoclast, gene
expression. Bone. 16:611–618.
12. Mitchell, R., C. Henning-Chubb, E. Huberman, and I.
Verma. 1986. c-fos expresssion is neither sufficient nor oblig-
atory for differentiation of monomyelocytes to macrophages.
Cell. 45:497–504.
13. Tanaka, S., M. Amling, L. Neff, A. Peyman, E. Uhlmann,
J.B. Levy, and R. Baron. 1996. c-Cbl is downstream of c-Src
in a signalling pathway necessary for bone resorption. Nature.
383:528–531.
14. Hertwig, P. 1942. Neue Mutationen und Kopplungsgruppen
bei der Hausmaus. Z. Indukt. Abstammungs-Vererbungsl. 80:
220–246.
15. West, J., G. Fisher, J. Loutit, M. Marshall, N. Nisbet, and H.
Perry. 1985. A new allele of microphthalmia induced in the
mouse: microphthalmia-defective iris (midi). Genet. Res., Camb.
46:309–324.
16. Nii, A., E. Steingrimsson, N. Copeland, N. Jenkins, and J.
Ward. 1995. Mild osteopetrosis in the microphthalmia-oak
ridge mouse. Am. J. Pathol. 147:1871–1882.
17. Thesingh, C., and J. Scherft. 1985. Fusion disability of em-
bryonic osteoclast precursor cells and macrophages in the mi-
crophthalmic osteopetrotic mouse. Bone. 6:43–52.
18. Hodgkinson, C.A., K.J. Moore, A. Nakayama, E. Stein-
grimsson, N.G. Copeland, N.A. Jenkins, and H. Arnheiter.
1993. Mutations at the mouse microphthalmia locus are asso-
ciated with defects in a gene encoding a novel basic-helix-
loop-helix-zipper protein. Cell. 74:395–404.
19. Hughes, J.J., J.B. Lingrel, J.M. Krakowsky, K.P. Anderson.
1993. A helix-loop-helix transcription factor–like gene is lo-
cated at the mi locus. J. Biol. Chem. 268:20687–20690.
20. Hemesath, T.J., E. Steingrimsson, G. McGill, M.J. Hansen, J.
Vaught, C.A. Hodgkinson, H. Arnheiter, N.G. Copeland,
N.A. Jenkins, D.E. Fisher. 1994. Microphthalmia, a critical
factor in melanocyte development, defines a discrete tran-
scription factor family. Genes Dev. 8:2770–2780.
21. Carr, C.S., and P.A. Sharp. 1990. A helix-loop-helix protein
related to the immunoglobulin E box-binding proteins. Mol.
Cell. Biol. 10:4384–4388.
22. Beckman, H., L.K. Su, and T. Kadesch. 1990. TFE3: a helix-
loop-helix protein that activates transcription through the
immunoglobulin enhancer uE3 motif. Genes Dev. 4:167–179.
23. Roman, C., A. Matera, C. Cooper, S. Artandi, S. Blain, D.
Ward, and L. Calame. 1992. mTFE3, an X-linked transcrip-
tional activator containing basic helix-loop-helix and zipper
domains, utilizes the zipper to stabilize both DNA binding
and multimerization. Mol. Cell. Biol. 12:817–827.
24. Zhao, G.Q., Q. Zhao, X. Zhou, M.G. Mattei, and B. De
Crombrugghe. 1993. TFEC, a basic helix-loop-helix protein,
forms heterodimers with TFE3 and inhibits TFE3-dependent
transcription activation. Mol. Cell. Biol. 13:4505–4512.
25. Yasumoto, K., and S. Shibahara. 1997. Molecular cloning of
cDNA encoding a human TFEC isoform, a newly identified
transcriptional regulator. Biochim. Biophys. Acta. 1353:23–31.
26. Blackwood, E.M., and R.N. Eisenman. 1991. Max: a helix-
loop-helix zipper protein that forms a sequence-specific
DNA-binding complex with Myc. Science. 251:1211–1217.
27. Merrell, K., S. Wells, A. Henderson, J. Gorman, F. Alt, A.
Stall, and K. Calame. 1997. The absence of the transcription
activator TFE3 impairs activation of B cells in vivo. Mol.
Cell. Biol. 17:3335–3344.
28. Tassabehji, M., V.E. Newton, and A.P. Read. 1994.
Waardenburg syndrome type 2 caused by mutations in the
human microphthalmia (MITF) gene. Nat. Genet. 8:251–255.
29. Hughes, A.E., V.E. Newton, X.Z. Liu, and A.P. Read. 1994.
A gene for Waardenburg syndrome type 2 maps close to the
human homologue of the microphthalmia gene at chromo-
some 3p12-p14.1. Nat. Genet. 7:509–512.
30. Moore, K.J. 1995. Insight into the microphthalmia gene. Trends
Genet. 11:442–448.
31. Steingrimsson, E., K.J. Moore, M.L. Lamoreux, A.R. Ferre-
D’Amare, S.K. Burley, D.C. Sanders-Zimring, L.C. Skow,
C.A. Hodgkinson, H. Arnheiter, N.G. Copeland, and N.A.
Jenkins. 1994. Molecular basis of mouse microphthalamia (mi)
mutations helps explain their developmental and phenotypic
consequences. Nat. Genet. 8:256–263.
32. Fisher, D.E., C.S. Carr, L.A. Parent, and P.A. Sharp. 1991.
TFEB has DNA-binding and oligomerization properties of a
unique helix-loop-helix/leucine-zipper family. Genes Dev. 5:
Address correspondence to David E. Fisher, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA
02115. Phone: 617-632-4916; Fax: 617-632-2085; E-mail: david_fisher@dfci.harvard.edu
Received for publication 16 October 1997 and in revised form 29 December 1997.785 Weilbaecher et al.
2342–2352.
33. Beckman, H., and T. Kadesch. 1991. The leucine zipper of
TFE3 dictates helix-loop-helix dimerization specificity. Genes
Dev. 5:1057–1066.
34. Fisher, D.E., L.A. Parent, and P.A. Sharp. 1993. High affinity
DNA-binding Myc analogs: recognition by an a helix. Cell.
72:467–476.
35. Moutier, R., K. Ostrowski, and H. Lamendin. 1989. Mi-
crophthalmia: a new recessive mutation in the Norway rat. J.
Hered. 90:76–78.
36. Cielinski, M., T. Iizuka, and S.C. Marks, Jr. 1994. Dental ab-
normalities in the osteopetrotic rat mutation microphthalmia
blanc. Arch. Oral Biol. 39:985–990.
37. Cielinski, M., and S.C. Marks, Jr. 1994. Neonatal reductions
in osteoclast number and function account for the transient
nature of osteopetrosis in the rat mutation microphthalmia
blanc (mib). Bone. 15:707–715.
38. Cielinski, M.J., and S.C. Marks, Jr. 1995. Bone metabolism
in the osteopetrotic rat mutation microphthalmia blanc. Bone.
165:567–574.
39. Takahashi, N., H. Yamana, S. Yoshiki, D. Roodman, G.
Mundy, S. Jones, A. Boyde, and T. Suda. 1988. Osteoclast-
like cell formation and its regulation by osteotropic hormones
in mouse bone marrow cultures. Endocrinology. 122:1373–
1382.
40. Shiina, Y., A. Yamaguchi, H. Yamana, E. Abe, S. Yoshiki,
and T. Suda. 1986. Comparison of the mechanisms of bone
resorption induced by 1,25-dihydroxyvitamin D3 and li-
popolysaccharides.  Calcif. Tissue Int. 39:28–34.
41. Takahashi, N., T. Akatsu, T. Sasaki, G. Nicholson, J. Mose-
ley, J. Martin, and T. Suda. 1988. Induction of calcitonin re-
ceptors by 1 alpha 25-dihydroxyvitamin D3 in osteoclast-
like multinucleated cells formed from mouse bone marrow
cells. Endocrinology. 123:1504–1510.
42. Takahashi, N., T. Akatsu, N. Udagawa, T. Sasaki, A.
Yamaguchi, J. Moseley, J. Martin, and T. Suda. 1988. Osteo-
blastic cells are involved in osteoclast formation. Endocrinol-
ogy. 123:2600–2602.
43. Sarma, U., and A. Flanagan. 1996. Macrophage colony-stim-
ulating factor induces substantial osteoclast generation and
bone resorption in human bone marrow cultures. Blood. 88:
2531–2540.
44. MacDonald, B., N. Takahashi, L. McManus, J. Holahan, G.
Mundy, and G. Roodman. 1987. Formation of multinucle-
ated cells that respond to osteotropic hormones in long term
human bone marrow cultures. Endocrinology. 120:2326–2333.
45. Tanaka, S., N. Takahashi, N. Udagawa, T. Tamura, T.
Akatsu, R. Stanley, T. Kurokawa, and T. Suda. 1993. Mac-
rophage colony-stimulating factor is indispensable for both
proliferation and differentiation of osteoclast progenitors. J.
Clin. Invest. 91:257–263.
46. Hemesath, T., E.R. Price, C. Takemota, T. Badalian, and D.
Fisher. 1998. MAPK links transcription factor microphthalmia
to c-Kit signaling in melanocytes. Nature. 391:298–301.
47. Lowings, P., U. Yavuzer, and C.R. Goding. 1992. Positive
and negative elements regulate a melanocyte-specific promoter.
Mol. Cell. Biol. 56:3653–3662.
48. Yasumoto, K., K. Yokoyama, K. Shibata, Y. Tomita, and S.
Shibahara. 1994. Microphthalmia-associated transcription factor
as a regulator for melanocyte-specific transcription of the hu-
man tyrosinase gene. Mol. Cell. Biol. 14:8058–8070.
49. Yasumoto, K., H. Mahalingam, H. Suzuki, M. Yoshizawa,
K. Yokoyama, and M. Shibahara. 1995. Transcriptional acti-
vation of the melanocyte-specific genes by the human ho-
molog of the mouse microphthalmia protein. J. Biochem. 118:
874–881.
50. Morii, E., T. Tsujimura, T. Jippo, K. Hashimoto, K. Takeba-
yashi, K. Tsujino, S. Nomura, M. Yamamoto, and Y. Kita-
mura. 1996. Regulation of mouse mast cell protease 6 gene
expression by transcription factor encoded by the mi locus.
Blood. 88:2488–2494.
51. Ebi, Y., Y. Kanakura, T. Jippo-Kanemoto, T. Tsujimura, T.
Furitsu, H. Ikeda, S. Adachi, T. Kasugai, S. Nomura, Y.
Kanayama, A. Yamatodani, et al. 1992. Low c-kit expression
of cultured mast cells of mi/mi genotype may be involved in
their defective responses to fibroblasts that express the ligand
for c-kit. Blood. 80:1454–1462.
52. Tsujimura, T., E. Morii, M. Nozaki, K. Hashimoto, Y.
Moriyama, K. Takebayashi, T. Kondo, Y. Kanakura, and Y.
Kitamura. 1996. Involvement of transcription factor encoded
by the mi locus in the expression of c-kit receptor tyrosine ki-
nase in cultured mast cells of mice. Blood. 88:1225–1233.786 Age-resolving Osteopetrosis: Model Implicating Microphthalmia and TFE3